Healthcare Services

Myasthenia Gravis Treatment Market Revenue Expected to Reach $2.43 Billion by 2030 with 8% CAGR

April 2, 2026April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Myasthenia Gravis Treatment Market At The End Of The 2026–2030 Forecast Period?

The myasthenia gravis treatment market has shown significant expansion in recent years. It is anticipated to increase from $1.66 billion in 2025 to $1.79 billion in 2026, registering a compound annual growth rate (CAGR) of 7.8%. The growth observed in previous periods is linked to the increasing occurrence of autoimmune disorders, the early adoption of corticosteroids, the extensive clinical application of cholinesterase inhibitors, the expansion of hospital-based MG treatment initiatives, and growing awareness of neuromuscular conditions.

The myasthenia gravis treatment market is anticipated to experience robust expansion over the coming years. Projections indicate it will reach $2.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. This growth during the forecast period is attributable to advancements in monoclonal antibody development, a surge in demand for minimally invasive surgical procedures, the proliferation of specialty clinics, increasing utilization of IVIG and cutting-edge immunotherapies, and improved diagnostic abilities through AI-powered tools. Key trends anticipated within the forecast period encompass the increasing embrace of immunosuppressive treatments, the expanding application of monoclonal antibodies for MG therapy, a growing preference for minimally invasive thymectomy, elevated demand for IVIG and plasmapheresis in severe instances, and the broadening scope of supportive and combination therapy methods.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp

What Drivers Are Shaping The Future Growth Of The Myasthenia Gravis Treatment Market?

The increasing incidence of myasthenia gravis is anticipated to fuel the expansion of the myasthenia gravis treatment market in the future. Myasthenia gravis is defined as an autoimmune neuromuscular disorder where individuals suffer from tiredness and muscle weakness affecting their skeletal muscles. Treating myasthenia gravis involves delivering healthcare services and patient care aimed at managing the disease. Consequently, the rise in myasthenia gravis cases is increasing revenue within the myasthenia gravis treatment market. For example, data from January 2024 by Myaware, a charity located in the UK, indicated that from a United Kingdom population of around 67,817,100, roughly 22,855 people are affected by myasthenia gravis, 204 by Lambert-Eaton myasthenic syndrome, and 2,103 by congenital myopathies. Hence, the heightened prevalence of myasthenia gravis is a key factor propelling the expansion of the myasthenia gravis treatment market.

What Segment Types Make Up The Myasthenia Gravis Treatment Market?

The myasthenia gravis treatment market covered in this report is segmented –

1) By Treatment: Anticholinesterase Agents, Immunosuppressants, Monoclonal Antibodies, Plasmapheresis Or Intravenous Immunoglobulin (IVIg), Thymectomy Or Surgical Options, Other Treatments

2) By Route Of Administration: Oral, Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Or E-commerce

4) By End User: Hospitals, Clinics, Other End-Users

Subsegments:

1) By Anticholinesterase Agents: Pyridostigmine, Neostigmine, Ambenonium

2) By Immunosuppressants: Corticosteroids, Azathioprine, Mycophenolate Mofetil, Cyclosporine, Tacrolimus

3) By Monoclonal Antibodies: Eculizumab, Rituximab

4) By Plasmapheresis Or Intravenous Immunoglobulin (IVIg): Plasma Exchange Therapy, IVIg Infusions

5) By Thymectomy Or Surgical Options: Transsternal Thymectomy, Minimally Invasive Thymectomy, Robot-Assisted Thymectomy

6) By Other Treatments: Symptomatic Therapy, Complement Inhibitors, Experimental Therapies

How Are Trends Impacting The Myasthenia Gravis Treatment Market?

Key companies operating in the myasthenia gravis treatment market are concentrating on developing innovative products like self-administered complement C5 inhibitors to improve treatment ease, boost patient independence, and reduce reliance on infusion-based care. Self-administered complement C5 inhibitors are specialized autoimmune therapies formulated for subcutaneous application, allowing patients to control excessive complement activation by administering treatment themselves at home instead of in clinical infusion environments. For instance, in October 2023, UCB Pharma, a Belgium-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) approved Zilucoplan. It is prescribed for adults with generalized myasthenia gravis (gMG) who are positive for anti-acetylcholine receptor (AChR) antibodies. This approval introduces a new option in the management of gMG, which manifests as muscle weakness due to an autoimmune response. ZILBRYSQ stands out as a self-administered, once-daily subcutaneous complement C5 inhibitor. This provides a convenient alternative to the traditional intravenous therapies that have been the standard for treating gMG.

Who Are The Key Players Driving Competition In The Myasthenia Gravis Treatment Market?

Major companies operating in the myasthenia gravis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Argenx SE, Immunovant Inc., Cabaletta Bio Inc., RemeGen Co. Ltd., Kedrion SpA

Read the full myasthenia gravis treatment market report here:

https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report

Which Geographic Regions Are Influencing Demand In The Myasthenia Gravis Treatment Market?

North America was the largest region in the myasthenia gravis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Myasthenia Gravis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11980&type=smp

Browse Through More Reports Similar to the Global Myasthenia Gravis Treatment Market 2026, By The Business Research Company

Muscle Spasticity Global Market Report

https://www.thebusinessresearchcompany.com/report/muscle-spasticity-global-market-report

Duchenne Muscular Dystrophy Global Market Report

https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-global-market-report

Muscle Pain Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/muscle-pain-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795